{
  "main_header": {
    "sid": 568580,
    "name": "Venus Remedies",
    "stock_name": "Venus Remedies",
    "full_name": "Venus Remedies Ltd",
    "name_url": "stocks-analysis/venus-remedies",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "305.00",
    "chg": 8.1,
    "chgp": "2.73%",
    "dir": 1,
    "prev_price": "296.90",
    "mcapval": "407.69 Cr",
    "mcap": "Micro Cap",
    "scripcode": 526953,
    "symbol": "VENUSREM",
    "ind_name": "Pharmaceuticals & Drugs",
    "ind_code": 4,
    "isin": "INE411B01019",
    "curr_date": "Apr 11, 12:53 PM",
    "curr_time": "00:11 AM",
    "bse_nse_vol": "5.99 k",
    "exc_status": "Active",
    "traded_date": "Apr 11, 2025",
    "traded_date_str": "2025 04 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://sandbox-www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/venus-remedies-568580-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Venus Remedies Reports Strong Q3 FY24-25 Performance Amid Market Challenges",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/venus-remedies-reports-q3-fy24-25-net-sales-of-rs-176-86-crore-amid-stock-downgrade-963458",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/VenusRemedies_mojoScore_410319.png",
        "date": "2025-02-11 19:07:14",
        "description": "Venus Remedies, a microcap pharmaceutical company, recently experienced a score adjustment following its third-quarter FY24-25 results, which highlighted strong debt servicing capabilities and significant operating profit growth. Despite facing challenges in the stock market, the company reported a notable increase in net sales and demonstrated healthy long-term growth potential."
      },
      {
        "title": "Venus Remedies Reports Strong Q4 Results with Significant Growth in Profit and Sales",
        "link": "https://www.marketsmojo.com/news/result-analysis/venus-remedies-reports-138-31-year-on-year-growth-in-q3-fy24-25-profit-before-tax-745959",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/VenusRemedies_quaterlyResult_355172.png",
        "date": "2025-02-05 10:02:53",
        "description": "Venus Remedies has announced its financial results for the quarter ending December 2024, revealing significant year-on-year growth in Profit Before Tax and Profit After Tax. Net sales increased notably, and the operating profit margin reached a five-quarter high, indicating improved efficiency and profitability for the company."
      },
      {
        "title": "Venus Remedies Hits 52-Week Low Amid Sustained Bearish Trend in Pharmaceuticals Sector",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/venus-remedies-hits-52-week-low-at-rs-280-amid-ongoing-decline-352806",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/1/VenusRemedies_priceRelatedfactors_263049.png",
        "date": "2025-01-28 11:05:20",
        "description": "Venus Remedies, a microcap in the Pharmaceuticals & Drugs sector, reached a new 52-week low today, continuing a five-day downward trend with a cumulative loss. Despite this, it outperformed its sector. The stock has struggled over the past year, significantly underperforming compared to the Sensex."
      }
    ],
    "total": 17,
    "sid": "568580",
    "stock_news_url": "https://sandbox-www.marketsmojo.com/news/venus-remedies-568580"
  },
  "announcements": [
    {
      "caption": "Closure of Trading Window",
      "datetime": "24-Mar-2025",
      "details": "Closure of trading window.",
      "source": "BSE"
    },
    {
      "caption": "Venus Remedies Gets Market Authorization For Anticoagulant Enoxaparin From Indonesia",
      "datetime": "10-Feb-2025",
      "details": "Venus Remedies gets Market Authorization for anticoagulant Enoxaparin from Indonesia",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "06-Feb-2025",
      "details": "UFR News paper publication.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Venus Remedies Ltd has declared <strong>30%</strong> dividend, ex-date: 23 Sep 13",
          "dt": "2013-09-23",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Venus Remedies Reports Strong Q3 FY24-25 Performance Amid Market Challenges

2025-02-11 19:07:14

Venus Remedies, a microcap pharmaceutical company, recently experienced a score adjustment following its third-quarter FY24-25 results, which highlighted strong debt servicing capabilities and significant operating profit growth. Despite facing challenges in the stock market, the company reported a notable increase in net sales and demonstrated healthy long-term growth potential.

Read More

Venus Remedies Reports Strong Q4 Results with Significant Growth in Profit and Sales

2025-02-05 10:02:53

Venus Remedies has announced its financial results for the quarter ending December 2024, revealing significant year-on-year growth in Profit Before Tax and Profit After Tax. Net sales increased notably, and the operating profit margin reached a five-quarter high, indicating improved efficiency and profitability for the company.

Read More

Venus Remedies Hits 52-Week Low Amid Sustained Bearish Trend in Pharmaceuticals Sector

2025-01-28 11:05:20

Venus Remedies, a microcap in the Pharmaceuticals & Drugs sector, reached a new 52-week low today, continuing a five-day downward trend with a cumulative loss. Despite this, it outperformed its sector. The stock has struggled over the past year, significantly underperforming compared to the Sensex.

Read More

View All News